These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9622147)

  • 1. Dose-related efficacy of irbesartan for hypertension: an integrated analysis.
    Reeves RA; Lin CS; Kassler-Taub K; Pouleur H
    Hypertension; 1998 Jun; 31(6):1311-6. PubMed ID: 9622147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.
    Fogari R; Ambrosoli S; Corradi L; Degli Esposti E; Mos L; Nami R; Nicrosini F; Pessina AC; Salvetti A; Vaccarella A; Zanchetti A; Martin A; Reeves RA
    J Hypertens; 1997 Dec; 15(12 Pt 1):1511-8. PubMed ID: 9431859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
    Kim SH; Jo SH; Lee SC; Lee SY; Yoon MH; Lee HL; Lee NH; Ha JW; Lee NH; Kim DW; Han GR; Hyon MS; Cho DG; Park CG; Kim YD; Ryu GH; Kim CH; Kim KS; Chung MH; Chae SC; Seung KB; Oh BH
    Clin Ther; 2016 Oct; 38(10):2171-2184. PubMed ID: 27742464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
    Chow CK; Thakkar J; Bennett A; Hillis G; Burke M; Usherwood T; Vo K; Rogers K; Atkins E; Webster R; Chou M; Dehbi HM; Salam A; Patel A; Neal B; Peiris D; Krum H; Chalmers J; Nelson M; Reid CM; Woodward M; Hilmer S; Thom S; Rodgers A
    Lancet; 2017 Mar; 389(10073):1035-1042. PubMed ID: 28190578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
    Zanchetti A
    J Hypertens Suppl; 1997 Dec; 15(7):S21-5. PubMed ID: 9532517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
    Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
    Kawano Y; Sato Y; Yoshinaga K
    Hypertens Res; 2008 Sep; 31(9):1753-63. PubMed ID: 18971554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women.
    Mirza FS; Ong P; Collins P; Okamura K; Gerhard-Herman M; Williams GH; Seely EW
    Menopause; 2008; 15(1):44-50. PubMed ID: 18182939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.